Archive for the ‘Cord Blood America Inc. CBAI’ Category

Cord Blood America, Inc. (CBAI) Posts FY2012 Financial Results, Offers Favorable View for 2013

Tuesday, April 2nd, 2013

Cord Blood America reported its full-year 2012 financial results for the 12 months ended December 31, 2012, reflecting a revamped business model.

Revenues for 2012 clipped a record $6.0 million, up 18 percent from $5.1 million reported in the year-ago period. Gross profit for the year increased by 20 percent to $4.20 million from $3.5 million reported in the comparable period of 2011. Administrative and selling expenses for the year decreased by 17 percent to $5.63 million, compared to $6.75 million for the year prior. Positive cash flow from operations increased 117 percent to $0.19 million vs. the year ago period.

Joseph Vicente, president of CBAI, said the company has reached a pivotal point to grow revenues and highlighted achievements in both domestic and international operations.

“After taking over as CEO in May of 2012, our team has made transformational changes to our business model as highlighted in the bullets above,” Vicente stated in the press release. “At the same time we recognize we are at an inflection point for the company where incremental revenue growth will drive significantly higher operating profit for the company, highlighting the leverage within our model. Our combined U.S. and South American operating divisions offer the best of both worlds, a high growth engine in Argentina, which grew revenue by 35 percent for the year is providing the annuity streams of tomorrow, combined with our U.S. operations which are growing at a steady rate of 10 percent while already achieving the scale to generate consistent recurring cash flow that covers the operation’s fixed cost, demonstrating further the power of building a sizable customer base.”

Vicente said he expects the upcoming year to maintain momentum as the company expands its offerings and strengthens its sales campaign.

“The last half of 2012 provided measureable improvement across key indicators for revenue, expenses and operating profit. As we progress into 2013, we are focused on expanding our service offerings in the stem cell space, securing additional sales channels to market our services, and ensuring that our sales efforts meet the balance of the fiscal discipline required to continue to build the cash position of the company, all key contributors to drive the future value for our shareholders,” Vicente concluded.

For more information visit www.cordblood-america.com

Let us hear your thoughts below:

Cord Blood America Inc. (CBAI) Posts First Half 2011 Results

Thursday, August 11th, 2011

Cord Blood America Inc. is the parent of CorCell, which facilitates umbilical cord blood stem cell preservation. Cord blood stem cells offer a potentially life-saving resource for treating a growing number of ailments including cancer, leukemia, blood and immune disorders.

The company today announced its financial results for the first half of 2011. It reported revenues of $2.89 million for the first six months of 2011, up 61% compared to revenues of $1.79 million in the same period in 2010. Revenues for the second quarter ended June 30, 2011 totaled $1.43 million, up 50% compared to 2010’s second quarter revenues of $951,561.

It has benefited from overseas acquisitions with foreign subsidiaries contributing $1.178 million towards the first six months revenue with the U.S. making up the rest. Cord Blood America’s gross profit for the first half of 2011 totaled $1.96 million, up 100% compared to last year’s total. It was up 76% from the 2010 second quarter period to $970,603.

Cord Blood America stated that it is continuing to develop further relationships with insurance companies. The company has also announced multiple new contracts in 2011 that it believes will fuel organic growth. It believes the trend toward smaller net losses and improved profitability will continue going forward.

For additional information on Cord Blood America, please visit www.corcell.com or www.cordblood-america.com

Let us hear your thoughts below:

Cord Blood America, Inc. (CBAI) Acquires NeoCells Assets

Monday, June 20th, 2011

Friday, Cord Blood America, Inc. announced that it had gained the assets of NeoCells for $320,000 during a foreclosure procedure. NeoCells is a subsidiary of Evanston, Illinois company ViviCells International, Inc.

Cord Blood America, parent company of CorCell, is an umbilical cord stem cell preservation company that works with parents who are expecting children. Aiming to be the “most respected stem cell preservation company in the industry”, Cord Blood collects stem cells from the umbilical cords of expectant mothers through a non-invasive process.

Matthew Schissler, co-founder and CEO of Cord Blood America said, “This is good news for our growth. CBAI has been highly acquisitive for a distinct reason. In today’s environment, with lots of companies struggling, we have found acquiring samples to be a very effective means to improve company gross margins,”

Schissler continued, “With this foreclosure, Cord Blood America has now added more than 2,700 customers this year through acquisition alone, not counting organic growth, including the previous purchase in February of all the umbilical cord blood samples from Reproductive Genetics Institute, Inc., also in Illinois. All customers have had their umbilical cord blood stem cells, which were saved at birth, moved to our Las Vegas headquarters. We’ve assumed the cryogenic storage of these samples, and billings from their contracts. We are excited to welcome the NeoCells customers to the Cord Blood America family.”

Let us hear your thoughts below:

Cord Blood America, Inc. (CBAI.OB) Praises Congress and President for Reauthorizing Umbilical Cord Blood Stem Cell Collection Legislation

Monday, November 8th, 2010

Cord Blood America, Inc. recently issued a press release praising the fact that Congress has approved, and President Obama has signed, the Stem Cell Therapeutic and Research Reauthorization Act of 2010.

Cord Blood America, parent company of CorCell, is an umbilical cord stem cell preservation company that works with parents who are expecting children. Aiming to be the “most respected stem cell preservation company in the industry”, Cord Blood collects stem cells from the umbilical cords of expectant mothers through a non-invasive process.

Matthew Schessler, co-founder, CEO and President of Cord Blood America said, “We believe there is a place for both public and private storage of umbilical cord blood stem cells and we salute Congress and the President for recognizing this important fact.”

He mentioned that Congressman Chris Smith (R-N.J., who wrote the original bill in 2005) said that research using stem cells is ongoing and expects their use to do “miraculous things”, such as aid in the treatments of cerebral palsy, lupus and genetic diseases including Krabbe disease, Hurler disease and Tay Sachs disease.

Congressman Smith said, “It remains one of the best kept secrets in America that umbilical cord blood stem cells are curing people of a myriad of terrible conditions and diseases. Umbilical cords are a rich, non-controversial source of stem cells, yet hospitals throw millions of them away each year. This law created a new nationwide umbilical cord blood stem cell program designed to collect, derive, type and freeze cord blood units for transplantation into patients to cure serious diseases such as childhood leukemia.”

U.S. Senator Jack Reed (D-RI), co-sponsor of the bill, said, “Cord blood is the blood that remains in the placenta and in the attached umbilical cord after childbirth. It is collected because it contains adult stem cells, which can be used to treat a range of diseases,” and that the bill will “help thousands of patients suffering from diseases requiring bone marrow and cord blood transplants.”

Let us hear your thoughts below:

Cord Blood America, Inc.’s (CBAI.OB) Six Month Overview Shows Explosive Growth Potential

Thursday, July 29th, 2010

Cord Blood America, Inc., www.cordblood-america.com – leaders in the innovative and life-saving science of preserving umbilical cord blood for future use in the treatment of diseases within the patient’s family, disclosed details regarding operations for the six-month period ending June 30, 2010.

Co-Founder and CEO, Matthew Schissler, characterized the six-month report as the most significant and eventful in the entire history of CBAI, projecting that if this pace of expansion and acquisitive activity were to continue, the Company is well within striking distance of becoming “the most significant stem cell company in the world.”

Kicking off 2010 with the Grand Opening of their new 17k sq ft stem cell lab and HQ – believed to be the largest such cryogenic storage facility/stem cell lab in the US – with 200+ investors and local and state dignitaries in attendance, CBAI immediately followed up on this huge boost with the announcement of an up to $16.8M funding commitment in January to fund acquisitions and strategic activity for the year.

Signing a letter of intent with Argentina’s biggest stem cell company, BioCells, Inc. ($1.5M per year in revenue), in January to process and store cord blood specimens, CBAI finalized the LOI in February and proceeded to announce intent to purchase controlling interest in the highly profitable firm in April.

The Company also announced signing of a placenta collection services agreement in April with an established and well-respected U.S. tissue bank for therapeutic transplantation purposes, which Schissler described as consisting of mostly sickle cell and leukemia treatments, noting ongoing research for applications in “diabetes, heart disease, stroke and other major medical conditions.”

Appointment of the President of the Nevada Oncology Society, Shamoon Ahmad, M.D., as CBAI’s Director of its Medical Advisory Board in February was a real feather in the Company’s cap, as Ahmad’s distinguished record in oncology and vast experience emboldened personnel throughout the ranks.

With acquisition of controlling interest in German cord blood banking leader stellacure GmbH (which operates with the German Red Cross) in March, CBAI secured an excellent European market foothold for expansion of services throughout Europe, while gaining yet another solid revenue engine ($1M+ projected for 2010).

The Company also signed a License and Cooperation Agreement in March in China with the intention of creating “the world’s largest cord blood bank in the world’s most populous nation.”

In May CBAI rolled-out the “Afford-A-Cord” which, by lowering the initial cost of stem cell storage to consumer levels, has opened up major new medical advances with stem cells to more families – a June analytical review indicates the new program should really boost new account additions.

Schissler pointed to the clear strategy of top-line focused goals, laid out for investors at the start of the year, which emphasized organic growth, acquisition, and revenue stream diversification as constituting a strong foundation built in the first half of 2010 which makes everyone very excited about the second half.

Schissler reaffirmed the core strategy and hinted to upcoming news that he believes will handsomely reward all of CBAI’s loyal shareholders.

Let us hear your thoughts below:

Cord Blood America, Inc. (CBAI.OB) Drops Initial Storage Fee Over 76%

Wednesday, May 26th, 2010

Cord Blood America, Inc., www.cordblood-america.com – markets a powerful umbilical cord blood stem cell preservation service using a proprietary cryogenic process via subsidiary CorCell, www.corcell.com – providing clients with an amazing way to invest in future, potentially life-saving medical treatments.

The Company announced today that CorCell will launch a new cost-reducing service for initial cell storage that will be offered as a payment option for established payment programs; the “Afford-A-Cord” program will only cost $495, a 76.2% savings that brings the option within striking distance of a much broader target market.

Co-founder and CEO of CBAI, Matthew Schissler, noted that the idea to create this service came from analysis of the target market and cited the upfront cost of the service as inordinate for families due to the timing; because of other costs associated with having a child, pressures and stresses, it is often very difficult for parents who want the best for their child’s future to take advantage of this breakthrough technology.

Schissler underscored the fact that the Company, as the undisputed price leader in this regard, is able to finally provide families searching for a solution to long-term health concerns, an affordable solution ($29/month for 18 years of storage after the birth) due in large part to CBAI’s strong financial position.

Schissler went on to say that he had firm faith in the concept that a variety of flexible payment plans was paramount to obtaining the maximum market penetration for CBAI’s services, and detailed the vast effort put into squaring away the legal and accounting aspects of the programs implementation, projecting a July 1, 2010 deadline launch date.

Schissler postulated that this would attract substantial new capital, and was confident that – between the added revenue from the program and the Company’s German branch in 2Q this year – CBAI would be setting a cord-blood subsidiary sales record this quarter.

Schissler stressed that Corcell’s current payment plans are, and will be, in full effect for the foreseeable future, and that the new Afford-A-Cord program is designed to lower the initial barrier for new customers, making the service available even for families with limited cash reserves.

The potential for stem cells is great and as the technologies emerge to utilize this resource, CBAI will be there to provide a winning service to customers and a return engine to investors.

Let us hear your thoughts below:

Cord Blood America, Inc. (CBAI.OB) Releases Update on First Quarter 2010 Achievements

Monday, May 24th, 2010

Cord Blood America, Inc., the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and families nationwide and internationally, recently released an update to investors on the company’s achievements during the first quarter of 2010.

Cord Blood America’s co-founder and chief executive officer, Matthew Schissler, reviewed first quarter results and progress in an interview with analyst Francis Gaskins. The entire interview is available at: www.gaskinsco.com/cbai-5-20-10.mp3.

Mr. Schissler noted in the interview that the company is on-track with its partnership with AXM Pharma to open the world’s largest stem cell storage and processing facility in China by January 2011. Additionally, management is continuing its due diligence on the acquisition of an Argentina stem cell company with affiliates throughout South America.

Mr. Schissler also stated that there was essentially no dilution of common stock in the first quarter and that the stock’s current price does not reflect the progress that the company continues to make in its expansion efforts.

For additional information, please visit www.corcell.com and www.cordblood-america.com.

Let us hear your thoughts below:

Cord Blood America (CBAI.OB) CEO Matthew Schissler Discusses Increasing Revenues in Analyst Interview

Wednesday, April 21st, 2010

One company that is starting to gain recognition on Wall Street is Cord Blood America. Located in Las Vegas, Nevada, Cord Blood is the parent company of CorCell which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Cord Blood is at the forefront of the healthcare sector and offers powerful and potential life-saving resources for treating a growing number of ailments which include cancer, leukemia, blood, and immune disorders.

Cord Blood’s leader Matthew Schissler, the co-founder and CEO of the growing corporation, agreed to an analyst interview recently and discussed increasing the company’s revenues. In the interview with analyst Francis Gaskins, Schissler stated that the focus for Cord Blood this year is top-line revenue growth. Schissler went on to highlight a number of reasons why Cord Blood is starting to gain recognition in the market place.

One of the main reasons Cord Blood is making waves in their field is the announcement that it is seeking to purchase controlling interest in a rising South American stem cell company. If this purchase is completed, Cord Blood could see an increase in revenue by $1.0 to $1.5 million in the next 12 month time frame.

Another reason revenues are looking up at Cord Blood is the purchase of a stem cell company in Germany. The company could add up to $1 million in revenues in the next year with this venture.

Cord Blood America recently went on a visit to China where its new facility will provide storage of 10 times the size of the company’s new Las Vegas laboratory which is believed to be the largest of its kind in U.S. – Operations are scheduled to begin in 2011.

Cord Blood has constantly provided hope and results to investors and has truly established a global presence. Currently, Cord Blood is trading in the $0.0097 range. With all of the highlights discussed by Matthew Schissler and even more in the company pipeline, Cord Blood could potentially become a dynamic force within the stem cell industry.

Let us hear your thoughts below:

Cord Blood America, Inc.’s (CBAI.OB) CEO Discusses China Expansion in Analyst Interview

Monday, April 5th, 2010

Cord Blood America, Inc., a provider of umbilical cord blood stem cell preservation for expectant parents and their children, recently announced that the company’s chief executive officer and co-founder, Matthew Schissler, was recently featured in an interview with analyst Francis Gaskins. In this interview, Mr. Schissler discusses the company’s expansion plans in China with AXM Pharma, Inc. (Pink Sheets: AXMP) to create the world’s largest stem cell storage facility.

Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood and immune disorders. The company’s expansion plans are based on the fact that a higher percentage of Chinese are interested in storing stem cells than in the U.S. and Europe. Although the barriers to entry into China are high and expensive, Cord Blood America’s partnership with AXM Pharma, Inc. will facilitate the company’s pathway to success. The entire interview is available at http://gaskinsco.com/cbai-3-31-10.mp3

Commenting on the company’s financial status, Mr. Schissler stated, “We now have a healthy balance sheet compared to where we were 12 months ago; the year 2010 will be dedicated to growing revenues.” Cord Blood America filed its annual financial report with the U.S. Securities & Exchange Commission last week.

Let us hear your thoughts below:

Cord Blood America, Inc. (CBAI.OB) Announces Agreement with BioCells, a Major South American Company

Tuesday, February 9th, 2010

Cord Blood America, Inc., the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children, recently announced that the company has secured an agreement with BioCells, Inc. to process and store cord blood specimens. BioCells, Inc., headquartered in Argentina with affiliates in Peru, Colombia, Bolivia, Panama and Puerto Rico, is the second-largest stem cell storage company in Argentina with annual revenues of $1.5 million (USD).

Cord Blood America utilizes a safe and non-invasive process to harvest cord blood stem cells that offer a powerful and potentially life-saving resource for treating a growing number of medical conditions, including cancer, leukemia, blood and immune disorders. The company recently opened a 17,000-square foot stem cell laboratory and headquarters in Las Vegas, Nevada.

Matthew Schissler, Cord Blood America co-founder and chief executive officer, stated, “BioCells is an outstanding firm and we are delighted to finalize this agreement.” Mr. Schissler added, “This transaction is an excellent example of how we are diversifying our revenue model with our new, increased storage capacity.”

Let us hear your thoughts below:

Cord Blood America Inc. (CBAI.OB) Announces Corporate Office Grand Opening in Las Vegas

Tuesday, January 19th, 2010

Cord Blood America Inc., an umbilical stem-cell preservation company, Friday announced that the Grand Opening of its Las Vegas, Nevada, corporate office and laboratory will run from noon until 5 p.m., January 22, 2010. The event features a board of speakers, both from the company and others from various state-side positions.

Speakers include Brian Krolicki, Nevada’s lieutenant governor; Somer Hollingsworth, president & CEO of Nevada Development Authority; and Michael Skaggs, executive director of the Nevada Commission on Economic Development.

Dr. Geoffrey John O’Neill, laboratory directory for CBAI, will discuss his extensive experience in the healthcare industry. Dr. O’Neill was part of the first bone marrow transplants in the 1970s, and has worked to achieve his vision of turning Cord Blood America into a “cellular pharmacy” for the world.

Among other company speakers is Joseph R. Vicente, an original CBAI board member, as well as Matthew Schissler, co-founder and CEO, who will discuss the overall stem-cell industry and the CBAI’s opportunities and plans for expansion through acquisitions.

CBAI’s new corporate office spans 17,000 square feet, a facility that includes a state-of-the-art laboratory for storage of multiple stem cell products. The company said it may be one of the largest cryogenic storage facility and stem cell labs in the nation.

Let us hear your thoughts below:

Cord Blood America (CBAI.OB) Up 45.45% Following Mention by QualityStocks

Tuesday, September 29th, 2009

Cord Blood America Inc. (OTCBB: CBAI) is up 45.45% today, trading at $0.008. This upward move has occurred on absolutely incredible volume of nearly 1 billion shares! Just a few days ago – on September 25th, QualityStocks highlighted the company in its daily newsletter when the stock was trading for only $0.0031 per share. Cord Blood America is already up 150% in a few short days.

The surge in the company’s stock price followed not only the mention by the QualityStocks newsletter, but also recent news from Cord Blood America – a company which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. The company reported that it is on schedule to complete the construction of its new Las Vegas laboratory by the first week of October. This lab will be perhaps one of the largest cryogenic storage labs in the US.

The subscriber base for the free QualityStocks Daily Newsletter continues to grow by leaps and bounds. From a modest start of only 100 subscribers in January 2006, there are now over 750,000 subscribers to the newsletter. The small cap and micro cap newsletter is like no other – readers are actually viewing data collected from hundreds of other newsletters. To subscribe to the newsletter, visit www.signup.qualitystocks.net.

Let us hear your thoughts below:

Cord Blood America, Inc. (CBAI.OB) Reduces an Additional $817,000 in Long-Term Debt

Thursday, April 23rd, 2009

Cord Blood America, Inc., an umbilical cord blood stem cell preservation company, announced today that it has eliminated $817,000 of long-term debt in addition to the recently announced long-term debt elimination of $1.75 million.

Matthew Schissler, Cord Blood America Founder and CEO, commented, “The remaining debt with YA Global Investments, formerly Cornell Capital Partners, has been assigned to an existing institutional investor. CBAI and YA Global Investments agreed on a one time common share settlement for liquidated damages in connection with assigning the outstanding principal and interest to the existing investor. With this assignment, CBAI has no further debt with YA Global Investments. Cord Blood America regards this as a key milestone on its path to being able to operate on its cash flow.”

“We said decreasing debt would be one of our significant items to focus on in 2009 and we are very pleased on how we are progressing,” added Mr. Schissler. “Eliminating debt makes out financial balance sheet stronger and makes Cord Blood America a better investment. We are very pleased with this development.”

Let us hear your thoughts below:

Cord Blood America (CBAI.OB) Hires Somerville to Get Their Message Out

Friday, March 20th, 2009

Cord Blood America, Inc., in support of its stated goal to become the most respected stem cell preservation company in the world, has selected a Los Angeles based public relations agency, Somerville Associates, to get the company’s message out. Cord Blood America provides families with the ability to preserve umbilical cord stem cells, which can be used by the family at a later date, if needed, to treat diseases and potentially save a family member’s life. The company feels that public education is, at this point, the most important thing they can do, and expects Somerville to play a key role in that effort.

Stem cells are increasingly seen as a valuable weapon in fighting a variety of diseases. The umbilical cord contains a rich store of stem cells, and provides a once-in-a-lifetime opportunity to capture and cryogenically preserve the cells for future use. As a result, the field of umbilical cord stem cell preservation is growing rapidly.

Cryogenically preserved umbilical cord stem cells have already been used to treat 75 major diseases, including leukemia, severe anemia, metabolic blood disorders, and immune deficiencies. In addition, medical research is currently underway to use these cells to combat heart disease, Parkinson’s disease, spinal cord injuries, sickle cell anemia, and various cancers.

It is possible, according to some researchers, that umbilical cord stem cells may someday be able to be turned into any tissue in the body. For example, damaged hearts could be repaired and stroke-damaged brain cells could be replaced. Notably, umbilical cord stem cells totally avoid the ongoing controversies surrounding stem cells from other sources, such as embryonic stem cells.

Founded in 2002, Cord Blood America has established itself as a platinum standard national competitor in the umbilical cord blood storage industry. The company seeks to provide education regarding this life-saving opportunity to expectant parents, as well as to families with a history of disease and critically ill patients. Cord Blood America has bundled services, such as medical kit preparation, courier arrangements, 24/7 customer service, and single pricing, to make the whole process easier.

Let us hear your thoughts: Cord Blood America Inc. Message Board

Cord Blood America, Inc. (CBAI.OB) Recognizes Significant Positives of President Obama’s Lifting of Stem Cell Funding Restrictions

Monday, March 9th, 2009

In a press release today, Cord Blood America, Inc. said that it believes the executive order signed today by President Obama eliminating restrictions on Federal funding of stem cell research is a “significant move forward for the entire stem cell sector.”

Matthew Schissler, Cord Blood America Founder and CEO, stated, “Scientists are confident that stem cell research will lead to fundamental improvements in the treatment of heart disease, diabetes, Parkinson’s disease and other of our most difficult to treat illnesses.”

“Stem cells are believed capable of becoming any tissue in the body, which could lead to treatments for illnesses currently impossible to cure,” Mr. Schissler continued. “The more positive news about stem cells and their medical uses, the more we believe parents and grandparents will understand the importance of umbilical cord blood stem cell storage, done at the time of birth by Cord Blood America.”

“Storing stem cells is the inventory business model needed for future therapies. As the stem cell research companies drive their respective trials forward, we’ll be ready with the inventory as therapies become commercialized. Without the inventory in storage, a great therapy can bypass a patient in need,” Mr. Schissler added.

Let us hear your thoughts: Cord Blood America Inc. Message Board

Cord Blood America, Inc. (CBAI.OB) Provides Details of Shareholder Meeting in Analyst Interview

Monday, February 23rd, 2009

Friday, Cord Blood America announced that founder and CEO Matthew Schissler provided details of the company’s special shareholder meeting in March. The details were given in an interview with analyst Francis Gaskins. The complete interview can be heard at: http://www.stoxrox.com/cbai-2-18-09-e.mp3

In the interview, Mr. Schissler explained why the company would like to increase its authorized shares. He said that authorized is “vastly different from outstanding” and the company has no commitments or understandings for the issuance of additional outstanding shares other than those currently on file at the SEC.

“Our goal is to be ahead of the game. We want to grow the Company into a global leader in the storage of stem cells and that includes the ability to act and react quickly. We also want to benefit from what we believe will be greatly increased research in this sector. This lets us control our destiny,” Mr. Schissler stated.

When asked why Cord Blood America is looking for such a large increase in authorized shares, the CEO replied, “This is a time-consuming, costly process and we only want to do it once in the Company’s history.”

Let us hear your thoughts: Cord Blood America Inc. Message Board

Cord Blood America Inc. (CBAI.OB): President Obama Guarantees Stem Cell Work

Friday, February 20th, 2009

Cord Blood America’s focus is on preserving stem cells, taken from the blood remaining in the umbilical cord and placenta after birth, to combat life-threatening illnesses. Research and development has shown that cord blood stem cells have tremendous future value for treating blood disorders and genetic diseases because the concordant stem cells in blood can be developed to match a patient’s own blood.

Earlier this month President Obama guaranteed lawmakers that he will sign an executive order overturning President Bush’s embryonic stem cell research policy. Mr. Obama said the executive order would be coordinated with Congress on timing and that it’s important Congress also pass a law codifying his order so that a future president can’t easily reverse the policy.

Dr. Neil Theise, an adult stem cell researcher and professor of pathology and medicine at the Beth Israel Medical Center of Albert Einstein College of Medicine in New York, said that a lifting of the embryonic stem cell research ban would “lift the need for political opposition to adult stem cell research, as well” and have benefits across the board for all forms of stem cell research.

By encouraging and supporting the research of stem cell science, more discoveries will be made and more diseases will become curable. As families see the increasing immediate benefits of preserving their children’s stem cells, more will demand Cord Blood America’s life-saving services. With a whole new medical field just beginning to be explored, the possibilities are endless.

Let us hear your thoughts: Cord Blood America Inc. Message Board

Cord Blood America, Inc. (CBAI.OB) is Focused on Becoming the Leader in Stem Cell Preservation

Wednesday, February 18th, 2009

Cord Blood America has made it a priority to be the most respected stem cell preservation company in the world. The company seeks to achieve its goal by educating expectant parents, families with a history of disease, critically ill patients, and all others who wish to learn about this life saving opportunity.

Founded in 2002, Cord Partners, a subsidiary of Cord Blood America, has established itself as a platinum standard national competitor in the umbilical cord blood storage industry. Cord Partners was founded by Matthew L. Schissler, Chairman and CEO, Stephanie Schissler, former President & COO, and Laura Fitzpatrick, former Vice President of Strategic Relations.

Cord Blood America, Inc. was founded on one, simple principle: The families who seek stem cell preservation should never have to work to achieve this. Cord Blood America has bundled services such as medical kit preparation, medical courier arrangement, 24/7 customer service, easy enrollment, and one price for all services, offering the highest quality stem cell preservation available.

Let us hear your thoughts: Cord Blood America Inc. Message Board

Cord Blood America, Inc. (CBAI.OB) Substantially Reduces Long Term Debt

Friday, February 13th, 2009

Yesterday, Cord Blood America announced that $1 million of long term debt has been eliminated between January 1, 2009 and February 12, 2009. The company previously expressed its desire to reduce debt and strengthen its balance sheet in press releases and CEO interviews. Cord Blood America plans to continue its effort to further reduce debt throughout 2009.

The company’s CEO Matthew Schissler stated, “It’s a start. De-levering our balance sheet coupled with strategic growth and acquisitions are the primary goals for 2009. I’m certain shareholders would agree that removing debts will help put the company in a strong position for long term growth in the stem cell industry.”

Let us hear your thoughts: Cord Blood America Inc. Message Board

Cord Blood America, Inc. (CBAI.OB) Ranks 20th Largest Bio Company in Los Angeles

Wednesday, April 23rd, 2008

The Los Angeles Business Journal announced today that Cord Blood America, Inc. (CBAI.OB) has been ranked as the 20th largest biotech/biomed company in Los Angeles. Cord Blood went public in 2003 and is the second youngest public company to be included on the list, with annual revenues of $6 million and 15 employees.

Cord Blood focuses on educating and assisting families in the benefits of storing life saving stem cells found in umbilical cords. Umbilical cord stem cells have successfully treated more than 70 medical conditions including leukemia, Hodgkin’s Disease, and anemia. Cord Blood provides 24/7 customer support with a full-time physician available for consultation and comprehensive testing, as well as a medical kit with supplies for collecting a newborn’s umbilical cord blood and packaging for transportation. The company’s mission is to become the most respected stem cell preservation company in the industry.

Matthew Schissler, CEO and Founder of Cord Blood America, said, “Our growth has both been rapid and extraordinary. It is nice to see the Company recognized for its achievements and we are proud of what we have accomplished in such a short period of time.”

Let us hear your thoughts: Cord Blood America Inc. Message Board

Cord Blood America Inc. (CBAI.OB) Reports a 74% Increase in 2007 Revenues

Wednesday, April 16th, 2008

Cord Blood America reported, before the market opened today, that total revenues for 2007 totaled $5.8 million. These revenues represent a 74% increase from the $3.3 million in total revenues generated in 2006. According to President and CEO of Cord Blood America, Matthew Schissler, there was a onetime charge of $500,000 deducted from the total revenues number to reflect a different way of accounting for yearly storage revenue, or the total would have been well north of $6 million.

Gross Profit for Cord Blood America was reported at an impressive $1.97 million, a 34% gross margin. This is a 604% increase from just $280,913 from the previous year, or a gross margin of just 8.5%. Schissler said that the results were drastically improved because of the company’s ability to reduce debt of their acquisitions and noted, “…the acquisition of CorCell, Inc. in Philadelphia, PA. was especially noteworthy.” On a closing note to the company’s performance, Schissler said, “We are pleased by our continued growth, encouraged that we have reduced our debt and some operating expenses, and confident that the storage of umbilical cord blood for the future treatment of significant diseases will continue to grow exponentially.”

The company continues to strategically align itself for success in the future. As people continue to realize the value that stem cell research holds, and the potential benefits of storing the valuable cells for the future, the company should continue to prosper. Today stem cells are being used in the treatment of leukemia, breast cancer, lymphoma, Hodgkin’s disease, aplastic anemia, sickle cell anemia, various other cancers, blood diseases, hereditary and genetic conditions, and immune system disorders.

Let us hear your thoughts: Cord Blood America Inc. Message Board

Cord Blood America Inc. (CBAI.OB) Seeks to Educate on the Benefits of Umbilical Cord Blood Preservation

Monday, April 14th, 2008

Cord Blood America Inc. (OTCBB: CBAI) recently announced it joined New York and California in passing a law aimed at educating pregnant women on the benefits of umbilical cord blood banking.

Cord Blood America’s goal is to become the most respected stem-cell preservation company in the world. Part of the company’s stated mission is to educate expectant parents on the life-saving opportunities available through umbilical blood cell preservation.

Umbilical cord cells are used to treat more than 70 diseases, including leukemia, lymphoma, anemia and immune deficient disorders. Educating expectant parents will not only save lives, but will provide direct information on the company and its services as well as raise awareness through word of mouth.

“We salute Pennsylvania for joining New York and California in taking the lead in providing solid, reliable information to potential new parents and believe this trend will continue in many more states,” Matthew Schissler, CEO of Cord Blood America said in a press release.

According to the Leukemia & Lymphoma Society, 44,240 new cases of leukemia were diagnosed in the United States in 2007. About 5,200 new cases of Acute Lymphocytic Leukemia, the most common form of leukemia in children/adults under the age of 19, were diagnosed in 2007. Leukemia is just one of the diseases umbilical cord blood storage can be used against.

Let us hear your thoughts: Cord Blood America Inc. Message Board

Cord Blood America (CBAI.OB) Announces Pennsylvania will educate Its Residents on the Benefits of Umbilical Cord Blood Storage

Friday, April 11th, 2008

Cord Blood America, Inc. (CBAI.OB) announced that Pennsylvania is the third state to pass a law focused on educating pregnant women and families on the benefits of umbilical cord blood storage. Pennsylvania’s Governor Edward G. Rendell signed House Bill 874 into law last week. The law will take effect in about 60 days.

In May 2007, Cord Blood America acquired CorCell, whose sales and marketing groups are headquartered in Philadelphia. During the process of acquiring the fourth largest umbilical cord bank in the U.S., Cord Blood America was able to establish strong relationships with state health insurers and the local medical community.

CEO of Cord Blood America, Matthew Schissler, said, “It is so important that families be informed about the benefits of umbilical cord blood storage, which is safe, non-controversial and is already used to treat more than 70 serious diseases, including various blood cancers such as leukemia, lymphoma and myelomas such as Hodgkin’s Disease, and blood diseases including anemia and immune deficient disorders.”

“We salute Pennsylvania for joining New York and California in taking the lead in providing solid, reliable information to potential new parents and believe this trend will continue in many more states,” Mr. Schissler continued.

Cord Blood America is an umbilical cord blood banking company focused on the preservation of life-saving stem cells for national and international use. Cord blood stem cells, which are collected through a safe and non-invasive process, have tremendous life-saving potential. The harvested stem cells can be banked for individual family use or can be banked for donation for families in need.

Let us hear your thoughts: Cord Blood America Inc. Message Board

Cord Blood America Inc. (CBAI.OB) Subsidiary is Making Cord Blood Storage Affordable for Everyone

Wednesday, April 9th, 2008

Cord Partners is a fully owned subsidiary of Cord Blood America, and it maintains same mission: to provide each and every family the opportunity to invest in their future health and the promise of regenerative medicine. The company accomplishes this mission by providing reliable, affordable, and – most importantly – accredited services to store cord blood stem cells. The company has been proving the success of this practice for more than ten years, and in that time has perfected its collection, processing, and storage techniques.

Cord Partners is committed to ensuring that the potentially lifesaving services offered are available to each and every family who wishes to participate in its programs. The company ensures this by offering a number of payment choices to meet the various financial needs of customers. These payment options include discounts and incentives for people paying up front, short and long-term interest-free monthly plans, and even a no-money down, annual plan which is the first of its kind in the cord blood industry.

The President and CEO of Cord Partners parent company, Cord Blood America, is Mr. Matthew Schissler. Due to the controversial nature of the company’s business, Schissler has spent a lot of time defending the company’s lifesaving technology. He has been quoted by the media for such strong, supporting statements as: “Stem cells are used today in the treatment of leukemia, breast cancer, lymphoma, Hodgkin’s Disease, aplastic anemia, sickle cell anemia, various other cancers, blood diseases, hereditary and genetic conditions and immune system disorders.” He has also stated, “As stem cell transplants become routine, they may be used to fight many other cancers, viruses and genetic disorders.”

Cord Blood America Incorporated was founded in Los Angeles, California in 2003, and has not only been collecting, testing and processing umbilical cords in the United States, but has also been actively engaging in advertising through print, radio and television for further support of its cause. In 2004, the company generated only $752,000 in revenues, which by 2005 had tripled to over $2.28 million. This steady increase has continued, as the company recorded revenues of $3.33 million in 2006 and is on pace to finish its 2007 fiscal year with nearly $8 million in total revenues.

Let us hear your thoughts: Cord Blood America Inc. Message Board

Cord Blood America, Inc. (CBAI.OB) – RainMakers International’s Project Media Placement Takes to the Racetrack

Monday, March 31st, 2008

RainMakers International, subsidiary of Cord Blood America (OTCBB: CBAI), is a full-service advertising agency based out of Santa Monica, Calif. The company focuses on radio, television, telephony on-hold and special project media placement. Rainmakers announced Friday it brokered and closed a deal for Microsoft to become a sponsor of NASCAR Sprint Cup No. 49 Team, BAM Racing.

“The power of this sponsorship is immeasurable,” Matthew Schissler, president of RainMakers stated in the press release. “What a wonderful opportunity for BAM Racing; we are proud to have closed this transaction.”

RainMakers’ role in the agreement revolves around its involvement in the new sponsorship program developed by ARMER Holding principals exclusively for BAM Racing. The Company offers project oriented media placement for radio, television, billboards, on-hold and special assignments. The company takes pride in its customer service solutions. According to RainMakers, an average of seven out of 10 callers are put on hold for about 38 seconds – this measures to an average person spending 1.2 years on hold.

The company’s on-hold packages include digital recording, editing and mixing; creative script writing, professional voice talent; a full range of music choices; licensed music; toll-free customer service; and quick turn-around time.

Let us hear your thoughts: Cord Blood America Inc. Message Board